10 Stocks Under $5 That Will Explode

7. Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Allogene Therapeutics, Inc. (NASDAQ:ALLO) secured a spot on our list of the best penny stocks set to explode.

As of April 8, 2026, analyst sentiment toward Allogene Therapeutics, Inc. (NASDAQ:ALLO) remains bullish, with 85% of analysts issuing “Buy” ratings on the stock. The consensus price target of $7.50 implies an upside of 186.26%.

On March 13, 2026, Piper Sandler increased its price target from $7 to $8 and kept an “Overweight” rating on Allogene Therapeutics, Inc. (NASDAQ:ALLO). The firm stated that investor attention was shifting to the April interim analysis from the ALPHA3 study in first-line consolidation LBCL, while noting a favorable setup for cema-cel to achieve a 25%–30% MRD clearance advantage over observation.

This development followed Allogene Therapeutics, Inc. (NASDAQ:ALLO)’s March 12, 2026, Q4 and full-year 2025 results, in which management referred to ALPHA3 as a significant turning point, while also noting that the study may determine whether allogeneic CAR-T can be administered at a biologic-like scale and grow beyond academic centers.

Allogene Therapeutics, Inc. (NASDAQ:ALLO) has $258.3 million in cash, cash equivalents, and investments at the end of 2025, extending the company’s runway into Q1 2028, while guiding to $150 million in operating cash expenses in 2026. Net loss for the fourth quarter was $38.8 million ($0.17 per share) versus a full-year net loss of $190.9 million, or $0.87 per share.

Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a clinical-stage biotechnology company dedicated to the development of off-the-shelf allogeneic CAR-T cell therapies for cancer and autoimmune diseases. The company’s goal is to provide a scalable, readily available cell therapy derived from healthy donors.